Evidence map›Paper›PMID 24872540›Full record

Trial reportJournal of the National Cancer Institute2014

Impact of lung cancer screening results on smoking cessation.

Martin C Tammemägi, Christine D Berg, Thomas L Riley, Christopher R Cunningham, Kathryn L Taylor

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the National Cancer Institute, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02267096 (Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening), which is not on this map. Cited by 121 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02267096 phase3completednot on this map

Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening

TypeinterventionalSponsorGeorgetown UniversityRan2014 to 2016Enrolled95ConditionsSmoking, Lung CancerArmsTelephone Counseling, Minimal Treatment
3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Biomedical risk assessment as an aid for smoking cessation.The Cochrane database of systematic reviews · 2019
    Pooled it
  6. Pooled it
  7. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018
    Guideline
  8. Guideline
  9. Predictors of Cessation Readiness among Cigarette Smokers Presenting for Low-Dose CT Lung Cancer Screening in Community Settings (WF-20817CD).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Martin C TammemägiAffiliations of authors: Department of Health Sciences, Brock University, St. Catharines, ON, Canada (MCT); Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD (CDB); Information Management Services, Rockville, MD (TLR, CRC); Department of Oncology, Lombardi Comprehensive Cancer Center, Cancer Control Program, Georgetown University, Washington, DC (KLT). martin.tammemagi@brocku.ca.
Christine D BergAffiliations of authors: Department of Health Sciences, Brock University, St. Catharines, ON, Canada (MCT); Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD (CDB); Information Management Services, Rockville, MD (TLR, CRC); Department of Oncology, Lombardi Comprehensive Cancer Center, Cancer Control Program, Georgetown University, Washington, DC (KLT).
Thomas L RileyAffiliations of authors: Department of Health Sciences, Brock University, St. Catharines, ON, Canada (MCT); Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD (CDB); Information Management Services, Rockville, MD (TLR, CRC); Department of Oncology, Lombardi Comprehensive Cancer Center, Cancer Control Program, Georgetown University, Washington, DC (KLT).
Christopher R CunninghamAffiliations of authors: Department of Health Sciences, Brock University, St. Catharines, ON, Canada (MCT); Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD (CDB); Information Management Services, Rockville, MD (TLR, CRC); Department of Oncology, Lombardi Comprehensive Cancer Center, Cancer Control Program, Georgetown University, Washington, DC (KLT).
Kathryn L TaylorAffiliations of authors: Department of Health Sciences, Brock University, St. Catharines, ON, Canada (MCT); Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD (CDB); Information Management Services, Rockville, MD (TLR, CRC); Department of Oncology, Lombardi Comprehensive Cancer Center, Cancer Control Program, Georgetown University, Washington, DC (KLT).

Funding

PROSTATE, LUNG, COLORECTAL, &OVARIAN CANCER SCREENINGN01CN025476 · CN · WESTAT, INC. · PI O'BRIEN, BARBARA B · 1992 to 2000
$7.9M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025512 · CN · HENRY FORD HEALTH SYSTEM · PI DEMERS, RAYMOND Y · 1992 to 2001
$2.0M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN075022 · CN · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FOUAD, MONA N. · 1997 to 2001
$1.6M
PROSTATE, LUNG, COLORECTAL &OVARIAN (PLCO) CANCERN01CN025516 · CN · WASHINGTON UNIVERSITY · PI ANDRIOLE, GERALD LOUIS · 1992 to 2001
$1.5M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025524 · CN · UNIVERSITY OF UTAH · PI BUYS, SAUNDRA S · 1992 to 2000
$1.5M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025514 · CN · UNIVERSITY OF COLORADO DENVER · PI CRAWFORD, E DAVID · 1992 to 2000
$1.3M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025515 · CN · PACIFIC HEALTH RESEARCH INSTITUTE · PI YOKOCHI, LANCE L · 1992 to 2000
$1.2M
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025511 · CN · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WEISSFELD, JOEL L · 1992 to 2000
$1.2M
PROSTATE, LUNG, COLORECTAL &OVARIAN CANCERN01CN025522 · CN · GEORGETOWN UNIVERSITY · PI GELMANN, EDWARD P · 1992 to 2000
$817k
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025513 · CN · UNIVERSITY OF MINNESOTA TWIN CITIES · PI CHURCH, TIMOTHY ROBERT · 1992 to 2001
$409k
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCERN01CN025518 · CN · MARSHFIELD CLINIC RESEARCH FOUNDATION · PI REDING, DOUGLAS · 1992 to 2000
$27k
NCI NIH HHS N01 CN025476NCI NIH HHS N01 CN025511NCI NIH HHS N01 CN025512NCI NIH HHS N01 CN025513NCI NIH HHS N01 CN025514NCI NIH HHS N01 CN025515NCI NIH HHS N01 CN025516NCI NIH HHS N01 CN025518NCI NIH HHS N01 CN025522NCI NIH HHS N01 CN025524NCI NIH HHS N01 CN075022NCI NIH HHS N01-CN-25511NCI NIH HHS N01-CN-25512NCI NIH HHS N01-CN-25513NCI NIH HHS N01-CN-25514NCI NIH HHS N01-CN-25515NCI NIH HHS N01-CN-25516NCI NIH HHS N01-CN-25518NCI NIH HHS N01-CN-25522NCI NIH HHS N01-CN-25524NCI NIH HHS N01-CN-75022NCI NIH HHS N02 CN063300NCI NIH HHS N02-CN-63300
6 · The paper itself

Abstract

backgroundLung cancer screening programs may provide opportunities to reduce smoking rates among participants. This study evaluates the impact of lung cancer screening results on smoking cessation.

methodsData from Lung Screening Study participants in the National Lung Screening Trial (NLST; 2002-2009) were used to prepare multivariable longitudinal regression models predicting annual smoking cessation in those who were current smokers at study entry (n = 15489, excluding those developing lung cancer in follow-up). The associations of lung cancer screening results on smoking cessation over the trial period were analyzed. All hypothesis testing used two sided P values.

resultsIn adjusted analyses, smoking cessation was strongly associated with the amount of abnormality observed in the previous year's screening (P < .0001). Compared with those with a normal screen, individuals were less likely to be smokers if their previous year's screen had a major abnormality that was not suspicious for lung cancer (odds ratio [OR] = 0.811; 95% confidence interval [CI] = 0.722 to 0.912; P < .001), was suspicious for lung cancer but stable from previous screens (OR = 0.785; 95% CI = 0.706 to 0.872; P < .001), or was suspicious for lung cancer and was new or changed from the previous screen (OR = 0.663; 95% CI = 0.607 to 0.724; P < .001). Differences in smoking prevalence were present up to 5 years after the last screen.

conclusionsSmoking cessation is statistically significantly associated with screen-detected abnormality. Integration of effective smoking cessation programs within screening programs should lead to further reduction in smoking-related morbidity and mortality.

Indexed as

Early Detection of CancerMass ScreeningAgedFemaleHumansLogistic ModelsLung NeoplasmsMaleMiddle AgedMultivariate AnalysisOdds RatioSmokingSmoking CessationTobacco Smoke PollutionUnited StatesTobacco Smoke Pollution

Identifiers

PMID24872540
PMCPMC4081623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.